Life Molecular Imaging and SOFIE Expand Partnership to Increase Availability of Neuraceq

Life Molecular Imaging (LMI) and SOFIE Biosciences announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq out of SOFIE's radiopharmaceutical manufacturing site located in Somerset, NJ. This agreement results in increased availability of Neuraceq for imaging centers, physicians, and patients with cognitive impairment in eastern Pennsylvania, New Jersey, and New York.

Neuraceq is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases.

"LMI is devoted to expanding access to Neuraceq for patients and physicians seeking confirmation of amyloid plaque in the brain, particularly for patients who are being evaluated for AD and may qualify for newly approved therapeutics. By increasing Neuraceq manufacturing capabilities in Somerset, NJ, in partnership with SOFIE, we are strengthening our efforts to meet the growing demand for amyloid PET imaging. This initiative underscores our devotion to enhancing patient access and supporting the medical and patient communities in this important area of healthcare," said Colleen Ruby, US Country Head, and Chief Operating Officer, Americas and APAC.

"SOFIE is proud to support the AD community through the manufacture and dispensing of Neuraceq. With the continued growth in amyloid targeting therapies, the diagnosis and staging using PET is more important than ever. We are excited to partner with LMI to continue rapidly increasing access to this important diagnostic tool," said Brian Schumer, PharmD, SOFIE Chief Operating Officer.